{
    "eid": "2-s2.0-85140621690",
    "title": "Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Anticoagulation",
        "Cancer",
        "Venous Thromboembolism"
    ],
    "authors": [
        "Lai Heng Lee",
        "Pongwut Danchaivijitr",
        "Noppacharn Uaprasert",
        "Harinder Gill",
        "Dennis Lee Sacdalan",
        "Gwo Fuang Ho",
        "Rajiv Parakh",
        "Paresh Pai",
        "Jen Kuang Lee",
        "Nannette Rey",
        "Alexander T. Cohen"
    ],
    "citedby-count": 0,
    "ref-count": 88,
    "ref-list": [
        "How I treat cancer-associated venous thromboembolism",
        "Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment",
        "Cancer-associated thrombosis",
        "Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study",
        "Cancer and venous thromboembolism",
        "Epidemiology and pathophysiology of cancer-associated thrombosis",
        "Aetiologies and prognosis of Chinese patients with deep vein thrombosis of the lower extremities",
        "Deep venous thrombosis in Taiwan",
        "Epidemiologic analysis of proximal deep vein thrombosis in Thai patients: malignancy, the predominant etiologic factor",
        "Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients",
        "Epidemiology of cancer-associated thrombosis in Asia: a systematic review",
        "Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study",
        "A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system",
        "Incidence of venous thromboembolism in Asian populations: a systematic review",
        "Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH",
        "Cancer-associated thrombosis: the when, how and why",
        "Mechanisms and risk factors of thrombosis in cancer",
        "Comparison between non-vitamin k antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism",
        "Thrombosis in cancer patients: etiology, incidence, and management",
        "Venous thrombosis and cancer: from mouse models to clinical trials",
        "Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis",
        "Cancer-associated venous thromboembolism: burden, mechanisms, and management",
        "Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants",
        "Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting",
        "Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges",
        "Epidemiology of venous thromboembolism",
        "The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE",
        "The diagnosis and treatment of venous thromboembolism in asian patients",
        "Cancer-associated thrombosis in Asia",
        "Development and validation of a predictive model for chemotherapy-associated thrombosis",
        "NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018",
        "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer",
        "Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications",
        "Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis",
        "Venous thromboembolism and cancer: current and future role of direct-acting oral anticoagulants",
        "Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice",
        "Cancer-associated thrombosis: improving patient adherence to low-molecular-weight heparin therapy",
        "Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis",
        "Anticoagulant therapy for venous thromboembolism in cancer",
        "Dabigatran versus warfarin in the treatment of acute venous thromboembolism",
        "Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II",
        "Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis",
        "Oral rivaroxaban for symptomatic venous thromboembolism",
        "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism",
        "Oral apixaban for the treatment of acute venous thromboembolism",
        "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism",
        "Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis",
        "Edoxaban for the treatment of cancer-associated venous thromboembolism",
        "Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)",
        "Apixaban for the treatment of venous thromboembolism associated with cancer",
        "Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial",
        "Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer study",
        "Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm",
        "Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study",
        "Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized controlled trials",
        "Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials",
        "Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis",
        "Direct oral anticoagulants for treatment of venous thromboembolism associated with cancer: a systematic review and meta-analysis",
        "The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: a systematic review and meta-analysis",
        "Evolving treatment options for cancer-related venous thromboembolism",
        "Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis",
        "Treatment patterns and clinical outcomes in Korean cancer patients with venous thromboembolism: a retrospective cohort study",
        "Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis",
        "Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer",
        "Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism",
        "Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats",
        "Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH",
        "2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)",
        "Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update",
        "2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer",
        "Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing",
        "American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer",
        "Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report",
        "Extending venous thromboembolism secondary prevention with apixaban in cancer patients: the EVE trial",
        "Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report",
        "NATF cancer-associated thrombosis project: introduction",
        "How I manage cancer-associated thrombosis",
        "Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis",
        "Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism",
        "Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score",
        "Global incidence and mortality of gastric cancer, 1980\u20132018",
        "Approach to cancer-associated thrombosis: challenging situations and knowledge gaps",
        "Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus",
        "Direct oral anticoagulants in cancer patients. time for a change in paradigm",
        "Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation",
        "Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Dasmarinas",
            "@id": "60109577",
            "affilname": "De La Salle Medical and Health Sciences Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60109577",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Gurugram",
            "@id": "60105731",
            "affilname": "Medanta - The Medicity",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60105731",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Manila",
            "@id": "60071449",
            "affilname": "University of the Philippines College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071449",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60017958",
            "affilname": "Singapore General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017958",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60013665",
            "affilname": "University of Malaya Medical Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013665",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "London",
            "@id": "60011520",
            "affilname": "King's College London",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011520",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Mumbai",
            "@id": "126718691",
            "affilname": "The Vascular Clinic",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126718691",
            "affiliation-country": "India"
        }
    ],
    "funding": [
        "Pfizer"
    ]
}